I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NXfE[5dY[3m2b4TvfIlkcXS7IHHzd4F6 MkfyglExOCEQvF2= NWe2SJcyTE2VTx?= NIP0eGtKSzVyPUK2JI5O NITqb|gzOTl4NEO0NC=>
RS4;11 MlPsZ5l1d3SxeHnjbZR6KGG|c3H5 NVnON5QzhjFyMDFOwG0> MnnSSG1UVw>? MWDJR|UxRTF7MjDuUS=> MXyyNVk3PDN2MB?=
MOLM13 NUTi[nZx[3m2b4TvfIlkcXS7IHHzd4F6 MVP+NVAxKM7:TR?= NFnieWNFVVOR M1rHXWlEPTB;MUKwJI5O MWiyNVk3PDN2MB?=
NOMO1 M36wS4N6fG:2b4jpZ4l1gSCjc4PhfS=> MUP+NVAxKM7:TR?= NVLrPHdvTE2VTx?= NI\ueI1KSzVyPUG1JI5O NHS2T2kzOTl4NEO0NC=>
HEL NXrCblNI[3m2b4TvfIlkcXS7IHHzd4F6 NEXud4l,OTByIN88US=> M{K2NWROW09? M1HOWmlEPTB;MTFOwG0> M1rpelIyQTZ2M{Sw
K562 NYLreZN[[3m2b4TvfIlkcXS7IHHzd4F6 M2Lzd54yODBizszN MkeySG1UVw>? Mn\3TWM2OD5zMECg{txO Mn[yNlE6PjR|NEC=
MEG01 M{S3eYN6fG:2b4jpZ4l1gSCjc4PhfS=> MUX+NVAxKM7:TR?= NHewfIpFVVOR MUnJR|UxRTJ3IN88US=> MomzNlE6PjR|NEC=
HL60 M2HWSIN6fG:2b4jpZ4l1gSCjc4PhfS=> MVr+NVAxKM7:TR?= M1;oUWROW09? NFrPW|FKSzVyPUi5NEBvVQ>? NYfLWo1zOjF7NkSzOFA>
MV4;11 NWTMbFlwSXCxcITvd4l{KGG|c3H5 MX;+NVAxKM7:TR?= M3;0PGROW09? NYXGOZBDcW6mdXPld{BieG:ydH;zbZM> M3juTlIyQTZ2M{Sw
MOLM13 NYLnTHQySXCxcITvd4l{KGG|c3H5 NU\E[2pPhjFyMDFOwG0> M1nV[mROW09? Mmj1bY5lfWOnczDhdI9xfG:|aYO= MV[yNVk3PDN2MB?=
MV4;11 NXjjPXhiTnWwY4Tpc44h[XO|YYm= NGf6bJBFVVOR Mmqy[IVkemWjc3XzJJRp\SC{ZXPyeYl1dWWwdDDv[kBDWkR|L{SgZY5lKGmvcHHpdoVlKHKnY4L1bZRu\W62IH;mJGNFUzliYX7kJHBCTjFidH:geIhmKHS{YX7zZ5JqeHSrb37hcEB{fGG{dDDzbZRm NFvycFYzOTl4NEO0NC=>
PBMC NHfKTWxHfW6ldHnvckBie3OjeR?= NVHUbYRETE2VTx?= NI[xfppqdmirYnn0d{BKVC14IIfpeIgheEmFNUCgc4YhPi55 M4DaXFIzPDN5MUG1
A2 NGHxfHhHfW6ldHnvckBie3OjeR?= NI\Ncnp,OTBizszN MYfEUXNQ MknPdoVi[3SrdnH0[ZMhdGG2ZX70JGhKXi1z M3XENFI{OjV3MkG4
A72 MYHGeY5kfGmxbjDhd5NigQ>? NIjKTFF,OTBizszN MXTEUXNQ NXfJTFAxemWjY4TpeoF1\XNibHH0[Y51KEiLVj2x NUH3UpNWOjN{NUWyNVg>
BC1 M{\FWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWX+NUDPxE1? MoHQSG1UVw>? MYHJR|UxRTJ{MDDuUS=> NUjqcJd[OjN5OUK0OFg>
BC3 MmjXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUP+NUDPxE1? MkL0SG1UVw>? NVPXdHY1UUN3ME20OlAhdk1? NHrpNnAzOzd7MkS0PC=>
BCBL1 NHXhZnJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYLNUmVwhjFizszN NX\aXoJsTE2VTx?= M2LoNGlEPTB;M{OwJI5O M{\BcFI{Pzl{NES4
BJAB MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGWxR3R,OSEQvF2= NGrURlZFVVOR NEjUTIJKSzVyPUm3NEBvVQ>? MnPyNlM4QTJ2NEi=
Namalwa MnXPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4fuTp4yKM7:TR?= MY\EUXNQ MkGzTWM2OD17N{Cgcm0> MUGyN|c6OjR2OB?=
Jurkat M1\KS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYjpc3VDhjFizszN NWfnd4NwTE2VTx?= Mn\vTWM2OD1zMkKwJI5O MU[yN|c6OjR2OB?=
MM1S NH\2Z2FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NInWdoR,OSEQvF2= NHf6TIVFVVOR MVjJR|UxRTd4MDDuUS=> Mlj1NlM4QTJ2NEi=
U266 NUPjZ|ZJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHnpe2x,OSEQvF2= NXG4VohrTE2VTx?= M4HZOmlEPTB;OUWwJI5O M1vKVFI{Pzl{NES4
UM-PEL-1 NHzhSHpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHr0fGl,OSEQvF2= MXnEUXNQ NHu4XJJKSzVyPUKxNEBvVQ>? NEO3e48zOzd7MkS0PC=>
UM-PEL-3 M2\lSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH\RSHN,OSEQvF2= NGH5UlJFVVOR MoXsTWM2OD1zOECgcm0> NVjVdYt3OjN5OUK0OFg>
BC1 NXPwVJlOTnWwY4Tpc44h[XO|YYm= M{fJNFUxOCCwTR?= MojqSG1UVw>? MYrpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 NETGfVQzOzd7MkS0PC=>
BC3 MYTGeY5kfGmxbjDhd5NigQ>? MXK1NFAhdk1? MUjEUXNQ MWHpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 Mkn4NlM4QTJ2NEi=
BC1 MY\GeY5kfGmxbjDhd5NigQ>? NHTpOGw5ODBibl2= NI\XdG1FVVOR MV3y[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz M1zkbFI{Pzl{NES4
BC3 NFLOcWhHfW6ldHnvckBie3OjeR?= MYK4NFAhdk1? MWjEUXNQ NUi0eWVuemWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? MUGyN|c6OjR2OB?=
H929 MX;GeY5kfGmxbjDhd5NigQ>? NUfyflFjhjFizszN M2f1XGROW09? MmfubY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MojBNlQ{OzV2OUm=
KMS12PE NXSweoxnTnWwY4Tpc44h[XO|YYm= NITz[JJ,OSEQvF2= NEfnWY1FVVOR MkLNbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MUmyOFM{PTR7OR?=
KMS12BM MXnGeY5kfGmxbjDhd5NigQ>? NGL2Ro5,OSEQvF2= M4DnU2ROW09? MWnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M2njPFI1OzN3NEm5
KMS18 NXP5R|ZXTnWwY4Tpc44h[XO|YYm= NUG5Znc{hjFizszN M1LYRmROW09? NGDRVYRqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NFOyZ3MzPDN|NUS5PS=>
KMS11 NYLV[nRoTnWwY4Tpc44h[XO|YYm= NWTsdXIzhjFizszN M2q5SWROW09? MofHbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NUH0XlJiOjR|M{W0PVk>
RPMI8226 NV:0N3hiTnWwY4Tpc44h[XO|YYm= NF\QUpl,OSEQvF2= NFnUOZdFVVOR NHXqPYhqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MoH5NlQ{OzV2OUm=
H929 Ml3QRZBweHSxc3nzJIF{e2G7 MXz+NUDPxE1? NUHnR5lJTE2VTx?= NHL2[VNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Mki2NlQ{OzV2OUm=
KMS12PE MljJRZBweHSxc3nzJIF{e2G7 NGDoVJV,OSEQvF2= NYjkUVVyTE2VTx?= MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmTiNlQ{OzV2OUm=
KMS12BM NUTvSpNSSXCxcITvd4l{KGG|c3H5 M3\FVJ4yKM7:TR?= NY\UR2NVTE2VTx?= NWDPXZQ6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGr5fYozPDN|NUS5PS=>
KMS18 NVvkR4VXSXCxcITvd4l{KGG|c3H5 NEjyZ2R,OSEQvF2= NX\4Xpo5TE2VTx?= Mne1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NGD5SWMzPDN|NUS5PS=>
KMS11 M4PI[mFxd3C2b4Ppd{Bie3OjeR?= NEmwXFN,OSEQvF2= NXH5NpY5TE2VTx?= NIjqT49qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlnZNlQ{OzV2OUm=
RPMI8226 NV;wWox1SXCxcITvd4l{KGG|c3H5 NXy1XWQ4hjFizszN MV\EUXNQ M3foTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWCyOFM{PTR7OR?=
U87MG MWHGeY5kfGmxbjDhd5NigQ>? NGXOdY9,OTBizszN MnGzSG1UVw>? NVXydXdbemWmdXPld{BWQDePRzDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEGuNFUh|ryP NVzYbI5sOjR2OU[zPFE>
A172 NV3xWlN[TnWwY4Tpc44h[XO|YYm= MVr+NVAh|ryP NH6ze|ZFVVOR NUW1O2s1emWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFEvOjhizszN M3q5RlI1PDl4M{ix
SW1783 NVvi[mIzTnWwY4Tpc44h[XO|YYm= NELVWVF,OTBizszN MmCxSG1UVw>? NHntT41z\WS3Y3XzJINmdGy3bHHyJGFVWCC5aYToJGlEPTBib3[gNk43QCEQvF2= NUDXNolpOjR2OU[zPFE>
U87MG MWXGeY5kfGmxbjDhd5NigQ>? MmnQglExKM7:TR?= MWLEUXNQ M{HB[4lv[3KnYYPld{Bxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOS:VIITyZY5{cXSrb36= MnWxNlQ1QTZ|OEG=
RAW267.4 M{XZSmZ2dmO2aX;uJIF{e2G7 NUfBeVlqOSEQvF2= NWDrWXgzTE2VTx?= MlrXdoVlfWOnczDJUE03KHC{b3T1Z5Rqd25iaX7keYNm\CCkeTDMVHM> NGjiS5MzPDh3OUCwPC=>
RAW267.4 NUK1e4kxTnWwY4Tpc44h[XO|YYm= MYOxJO69VQ>? MnfWSG1UVw>? M1zCWJJm\HWlZYOgeIhmKGG|c3;jbYF1cW:wIHLleJdm\W5iQmLEOEBidmRiYXPleJlt[XSnZDDwOlU> NHPFZmMzPDh3OUCwPC=>
Me007 M2HXcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVzZc2lQhjFyMDFOwG0> NX;UZ5ozTE2VTx?= MnXzbY5pcWKrdIOgeIhmKGe{b4f0bC=> NVTudIlGOjR7ME[xN|c>
SK-Mel-28 NYLafmlrT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFnvPIF,OTByIN88US=> MVrEUXNQ NUSyZ4FmcW6qaXLpeJMhfGinIHfyc5d1cA>? M{PqTVI1QTB4MUO3
Mel-RMU MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEnITWd,OTByIN88US=> MWPEUXNQ NVnBcIoycW6qaXLpeJMhfGinIHfyc5d1cA>? NFf3PXczPDlyNkGzOy=>
Mel-JD MmTqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYT5bWVNhjFyMDFOwG0> NGTxZ|FFVVOR NVexdYVVcW6qaXLpeJMhfGinIHfyc5d1cA>? NV7TNYRIOjR7ME[xN|c>
Mel-RM M3PVTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NETQb2V,OTByIN88US=> NUG4RXQ{TE2VTx?= NVjMTopLcW6qaXLpeJMhfGinIHfyc5d1cA>? MUeyOFkxPjF|Nx?=
Me007 NHrpN|lCeG:ydH;zbZMh[XO|YYm= MWn+NVAxKM7:TR?= MYXEUXNQ M{X4R4lv\HWlZYOgZZBweHSxc3nz NWTr[2VFOjR7ME[xN|c>
SK-Mel-28 M{T4SmFxd3C2b4Ppd{Bie3OjeR?= Ml7rglExOCEQvF2= M1zUXWROW09? M4nneYlv\HWlZYOgZZBweHSxc3nz NGjteYQzPDlyNkGzOy=>
Mel-RMU NEL5dGdCeG:ydH;zbZMh[XO|YYm= NXvTfXdzhjFyMDFOwG0> MYLEUXNQ MYrpcoR2[2W|IHHwc5B1d3Orcx?= MWKyOFkxPjF|Nx?=
Mel-JD M1jNVGFxd3C2b4Ppd{Bie3OjeR?= Mo\6glExOCEQvF2= MWHEUXNQ MV;pcoR2[2W|IHHwc5B1d3Orcx?= Mn;INlQ6ODZzM{e=
Mel-RM NWrGR2lESXCxcITvd4l{KGG|c3H5 MWT+NVAxKM7:TR?= M335[mROW09? NGHKdXBqdmS3Y3XzJIFxd3C2b4Ppdy=> NF\P[44zPDlyNkGzOy=>
Me007 MW\GeY5kfGmxbjDhd5NigQ>? M{XBflExKM7:TR?= MVrEUXNQ M4njbolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NXm1PJhbOjR7ME[xN|c>
SK-Mel-28 NV7rUJFuTnWwY4Tpc44h[XO|YYm= MoriNVAh|ryP NH\HOolFVVOR Ml3XbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MmjWNlQ6ODZzM{e=
Mel-RMU MoSzSpVv[3Srb36gZZN{[Xl? NYfFeod[OTBizszN NUGxUHZXTE2VTx?= Mn7xbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy M1vBN|I1QTB4MUO3
Mel-JD MnPhSpVv[3Srb36gZZN{[Xl? NICw[2kyOCEQvF2= MXfEUXNQ NWKzTXhlcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz MVqyOFkxPjF|Nx?=
Mel-RM NYjYeZVKTnWwY4Tpc44h[XO|YYm= NUTrd4IzOTBizszN MUDEUXNQ MYfpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> MkH6NlQ6ODZzM{e=
Me007 MnzvSpVv[3Srb36gZZN{[Xl? NYjiUYFpOTBizszN M1y5cmROW09? NGHlRoF2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz NV2x[XJHOjR7ME[xN|c>
SK-Mel-28 M{XhW2Z2dmO2aX;uJIF{e2G7 M3H5cFExKM7:TR?= NGLoSoFFVVOR NEDGdml2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz M1m3TlI1QTB4MUO3
Mel-RMU NWrocJdKTnWwY4Tpc44h[XO|YYm= NFThRpUyOCEQvF2= NVn3[VFLTE2VTx?= M3nRcJVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NXLn[215OjR7ME[xN|c>
Mel-JD MX7GeY5kfGmxbjDhd5NigQ>? NGjqOooyOCEQvF2= MXXEUXNQ NVvFeIN2fXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MmLTNlQ6ODZzM{e=
Mel-RM M3HOV2Z2dmO2aX;uJIF{e2G7 MVqxNEDPxE1? M4TKNGROW09? NVX1Z2RTfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MlvJNlQ6ODZzM{e=

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID